Floatz logo

Optimized Neoantigen Synthetic Long Peptide Vaccine

Gastroesophageal Adenocarcinoma

Washington University School of MedicinevaccinePhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

40 Active assets in the Gastroesophageal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Diwakar Davar
Phase 3BB
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
Nivolumab
Memorial Sloan Kettering Cancer Center
Phase 2BB
TRASTUZUMAB
UNICANCER
Phase 3BB
Capecitabine
Shanghai Zhongshan Hospital
Phase 3B

View all 50 →

Same molecule, other indications

Optimized Neoantigen Synthetic Long Peptide Vaccine is also rated in:

infiltrating bladder urothelial carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
malignant pancreatic neoplasmDormant
CC
Indicative ·
42 / 100
View asset →
pancreatic neoplasmDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →